Arcturus to present new Phase 1b interim data for ARCT-032 at European Cystic Fibrosis Conference on June 7, 2024
First four CF patients demonstrated an average improvement of 4% FEV1 after two ...
Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments